Aurinia Pharmaceuticals (AUPH) Short Interest Ratio & Short Volume $7.49 +0.01 (+0.13%) Closing price 04:00 PM EasternExtended Trading$7.52 +0.02 (+0.33%) As of 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Aurinia Pharmaceuticals Short Interest DataAurinia Pharmaceuticals (AUPH) has a short interest of 10.53 million shares, representing 8.82% of the float (the number of shares available for trading by the public). This marks a 0.29% increase in short interest from the previous month. The short interest ratio (days to cover) is 8.7, indicating that it would take 8.7 days of the average trading volume of 1.37 million shares to cover all short positions.Current Short Interest10,530,000 sharesPrevious Short Interest10,500,000 sharesChange Vs. Previous Month+0.29%Dollar Volume Sold Short$86.14 millionShort Interest Ratio8.7 Days to CoverLast Record DateJune 15, 2025Outstanding Shares135,100,000 sharesFloat Size119,370,000 sharesShort Percent of Float8.82%Today's Trading Volume2,249,656 sharesAverage Trading Volume1,368,129 sharesToday's Volume Vs. Average164% Short Selling Aurinia Pharmaceuticals? Sign up to receive the latest short interest report for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartAUPH Short Interest Over TimeAUPH Days to Cover Over TimeAUPH Percentage of Float Shorted Over Time Aurinia Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/15/202510,530,000 shares $86.14 million +0.3%8.8%8.7 $8.18 5/31/202510,500,000 shares $82.53 million -3.5%8.7%8.2 $7.86 5/15/202510,880,000 shares $88.67 million -3.3%9.1%7.5 $8.15 4/30/202511,250,000 shares $92.70 million +2.8%9.3%8.2 $8.24 4/15/202510,940,000 shares $84.79 million -4.8%9.0%8 $7.75 3/31/202511,490,000 shares $92.38 million +0.4%9.4%7.8 $8.04 3/15/202511,440,000 shares $93.35 million -0.6%9.4%8.1 $8.16 2/28/202511,510,000 shares $91.50 million +15.5%9.4%7.9 $7.95 2/15/20259,970,000 shares $77.67 million +6.2%7.3%7.5 $7.79 1/31/20259,390,000 shares $74.65 million +25.5%N/A6.6 $7.95 Get the Latest News and Ratings for AUPH and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/15/20257,480,000 shares $57.52 million +29.2%N/A5.3 $7.69 12/31/20245,790,000 shares $51.99 million +4.7%N/A4.4 $8.98 12/15/20245,530,000 shares $51.82 million -11.1%N/A4.5 $9.37 11/30/20246,220,000 shares $55.11 million -9.6%N/A4.9 $8.86 11/15/20246,880,000 shares $55.87 million -6.3%N/A5.5 $8.12 10/31/20247,340,000 shares $52.92 million +2.1%N/A5.9 $7.21 10/15/20247,190,000 shares $51.77 million -0.7%N/A5.7 $7.20 9/30/20247,240,000 shares $53.07 million -4.5%N/A5.2 $7.33 9/15/20247,580,000 shares $53.29 million -13.0%N/A5.3 $7.03 8/31/20248,710,000 shares $59.32 million +2.7%N/A6.3 $6.81 8/15/20248,480,000 shares $47.40 million -13.8%N/A6.5 $5.59 7/31/20249,840,000 shares $57.86 million +13.1%N/A7.5 $5.88 7/15/20248,700,000 shares $49.33 million -15.7%N/A6.8 $5.67 6/30/202410,320,000 shares $58.93 million +1.4%N/A8.3 $5.71 6/15/202410,180,000 shares $57.52 million +10.5%N/A8 $5.65 5/31/20249,210,000 shares $49.92 million -20.1%N/A6.8 $5.42 5/15/202411,530,000 shares $61.22 million +12.4%N/A7.5 $5.31 4/30/202410,260,000 shares $52.22 million -9.9%8.1%5 $5.09 4/15/202411,390,000 shares $57.41 million -6.9%8.9%5.5 $5.04 3/31/202412,240,000 shares $61.32 million +14.9%9.6%5.2 $5.01 3/15/202410,650,000 shares $55.06 million -12.0%8.3%4.5 $5.17 2/29/202412,100,000 shares $69.21 million -28.2%9.5%4.9 $5.72 2/15/202416,850,000 shares $101.44 million -9.1%13.2%6.7 $6.02 1/31/202418,530,000 shares $139.72 million +13.1%N/A9.1 $7.54 1/15/202416,390,000 shares $126.86 million +5.3%N/A7.9 $7.74 12/31/202315,570,000 shares $139.97 million -4.6%N/A7.8 $8.99 12/15/202316,320,000 shares $153.24 million -4.6%N/A8.2 $9.39 11/30/202317,110,000 shares $147.83 million -0.5%N/A8.9 $8.64 11/15/202317,190,000 shares $140.27 million -0.5%N/A9.2 $8.16 10/31/202317,280,000 shares $126.84 million -0.9%N/A10 $7.34Is Elon's empire crumbling? (Ad)The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd. Click here to see the Tesla shock that could blindside everyone. 10/15/202317,430,000 shares $131.07 million +2.4%N/A8.4 $7.52 9/30/202317,030,000 shares $132.32 million +0.1%N/A8 $7.77 9/15/202317,010,000 shares $150.37 million +21.9%N/A7.8 $8.84 8/31/202313,960,000 shares $126.62 million -16.4%N/A6.5 $9.07 8/15/202316,700,000 shares $159.99 million +5.6%N/A7.2 $9.58 7/31/202315,820,000 shares $183.20 million -5.3%N/A6.5 $11.58 7/15/202316,710,000 shares $185.82 million +6.8%N/A6.9 $11.12 6/30/202315,650,000 shares $151.49 million -1.2%N/A6.2 $9.68 6/15/202315,840,000 shares $157.29 million -5.2%N/A5.9 $9.93 5/31/202316,700,000 shares $149.63 million +7.6%N/A5.7 $8.96 5/15/202315,520,000 shares $168.86 million -7.1%N/A5 $10.88 4/30/202316,710,000 shares $187.99 million -3.1%13.1%5.5 $11.25 4/15/202317,250,000 shares $193.55 million -0.2%13.5%5.9 $11.22 3/31/202317,280,000 shares $189.39 million +5.5%N/A5.6 $10.96 3/15/202316,380,000 shares $155.61 million +9.5%N/A5.1 $9.50 2/28/202314,960,000 shares $135.99 million +18.1%N/A5.1 $9.09 2/15/202312,670,000 shares $99.33 million +14.9%N/A4.6 $7.84 1/31/202311,030,000 shares $99.82 million +48.9%N/A3.8 $9.05 1/15/20237,410,000 shares $67.51 million -2.0%N/A2.3 $9.11 12/30/20227,560,000 shares $32.66 million -10.0%N/A2.5 $4.32 12/15/20228,400,000 shares $38.05 million -4.6%N/A3.5 $4.53 11/30/20228,800,000 shares $45.14 million +6.2%N/A3.5 $5.13 11/15/20228,290,000 shares $42.69 million -27.7%N/A3.3 $5.15 10/31/202211,460,000 shares $93.17 million -4.0%N/A4.9 $8.13 10/15/202211,940,000 shares $87.64 million -4.5%N/A4.9 $7.34 9/30/202212,500,000 shares $94 million +4.5%N/A5.4 $7.52 9/15/202211,960,000 shares $90.66 million -4.6%N/A4.4 $7.58 8/31/202212,530,000 shares $92.22 million -6.1%N/A4.5 $7.36 8/15/202213,340,000 shares $115.12 million -2.5%N/A4.9 $8.63 7/31/202213,680,000 shares $111.90 million -1.2%N/A4.7 $8.18 7/15/202213,840,000 shares $145.18 million -3.0%N/A5.5 $10.49 6/30/202214,260,000 shares $143.31 million +48.4%11.7%5.8 $10.05 6/15/20229,610,000 shares $95.24 million -6.5%7.9%4.2 $9.91 5/31/202210,280,000 shares $115.96 million +7.5%8.3%4.8 $11.28 5/15/20229,560,000 shares $106.79 million -8.4%7.7%3.3 $11.17 4/30/202210,440,000 shares $107.43 million +3.0%8.3%3.6 $10.29 4/15/202210,140,000 shares $120.16 million +13.9%8.1%3.3 $11.85 3/31/20228,900,000 shares $110.18 million -0.1%7.2%2.7 $12.38 3/15/20228,910,000 shares $93.47 million -8.9%7.2%2.6 $10.49 2/28/20229,780,000 shares $120.29 million -10.8%7.9%2.7 $12.30 2/15/202210,960,000 shares $205.94 million +15.7%9.8%3.2 $18.79 1/31/20229,470,000 shares $157.77 million -18.2%8.7%2.5 $16.66 1/15/202211,570,000 shares $228.04 million +9.2%10.6%2.6 $19.71 12/31/202110,600,000 shares $242.42 million -7.7%9.4%2.4 $22.87 12/15/202111,480,000 shares $228.11 million +26.2%10.2%2.5 $19.87 11/30/20219,100,000 shares $171.44 million -14.7%8.1%1.9 $18.84 11/15/202110,670,000 shares $288.41 million -12.2%9.5%2.2 $27.03 10/29/202112,150,000 shares $401.92 million -29.1%11.4%2.8 $33.08 10/15/202117,130,000 shares $352.36 million -6.0%16.2%3.8 $20.57 9/30/202118,230,000 shares $403.43 million -2.4%17.3%4.3 $22.13Is Elon's empire crumbling? (Ad)The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd. Click here to see the Tesla shock that could blindside everyone. 9/15/202118,670,000 shares $388.15 million +7.0%17.7%4.6 $20.79 8/31/202117,450,000 shares $284.09 million -0.9%16.5%4.8 $16.28 8/13/202117,600,000 shares $266.99 million +4.4%16.7%5 $15.17 7/30/202116,860,000 shares $228.62 million +26.3%16.0%4.3 $13.56 7/15/202113,350,000 shares $152.86 million +4.1%12.0%3.6 $11.45 6/30/202112,830,000 shares $166.28 million -4.1%11.5%3.5 $12.96 6/15/202113,380,000 shares $164.98 million +4.3%12.0%3.9 $12.33 5/28/202112,830,000 shares $186.29 million +27.4%11.5%3.5 $14.52 5/14/202110,070,000 shares $110.37 million +22.7%9.1%2.7 $10.96 4/30/20218,210,000 shares $99.18 million -3.8%7.4%2.2 $12.08 4/15/20218,530,000 shares $107.39 million +4.8%7.7%2.1 $12.59 3/31/20218,140,000 shares $102.08 million -0.5%7.4%1.8 $12.54 3/15/20218,180,000 shares $112.56 million +37.5%7.4%1.7 $13.76 2/26/20215,950,000 shares $86.75 million +9.4%5.4%1.3 $14.58 2/12/20215,440,000 shares $86.77 million +0.7%5.0%1.4 $15.95 1/29/20215,400,000 shares $92.23 million +20.8%5.2%1.5 $17.08 1/15/20214,470,000 shares $64.64 million -12.7%4.1%1.4 $14.46 12/31/20205,120,000 shares $71.48 million -1.9%4.7%2.9 $13.96 12/15/20205,220,000 shares $78.40 million -5.1%4.8%3.6 $15.02 11/30/20205,500,000 shares $80.19 million +7.4%5.0%5.3 $14.58 11/15/20205,120,000 shares $68.61 million +20.5%4.7%4.9 $13.40 10/30/20204,250,000 shares $68.09 million +9.8%3.9%4.2 $16.02 10/15/20203,870,000 shares $60.29 million -7.4%3.6%3.6 $15.58 9/30/20204,180,000 shares $61.57 million -2.3%3.9%2.8 $14.73 9/15/20204,280,000 shares $63.81 million -2.7%4.0%2.8 $14.91 8/31/20204,400,000 shares $65.25 million +6.0%4.1%2.9 $14.83 8/14/20204,150,000 shares $58.14 million -6.5%4.0%2.6 $14.01 7/31/20204,440,000 shares $62.74 million -3.1%5.1%2.9 $14.13 7/15/20204,580,000 shares $67.37 million -5.2%5.2%3.1 $14.71 AUPH Short Interest - Frequently Asked Questions What is Aurinia Pharmaceuticals' current short interest? Short interest is the volume of Aurinia Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of June 15th, traders have sold 10,530,000 shares of AUPH short. 8.82% of Aurinia Pharmaceuticals' shares are currently sold short. Learn More on Aurinia Pharmaceuticals' current short interest. What is a good short interest ratio for Aurinia Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. AUPH shares currently have a short interest ratio of 9.0. Learn More on Aurinia Pharmaceuticals's short interest ratio. Which institutional investors are shorting Aurinia Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Aurinia Pharmaceuticals: Jane Street Group LLC, Caption Management LLC, Walleye Capital LLC, Simplex Trading LLC, and Jefferies Financial Group Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Aurinia Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.82% of Aurinia Pharmaceuticals' floating shares are currently sold short. Is Aurinia Pharmaceuticals' short interest increasing or decreasing? Aurinia Pharmaceuticals saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 10,530,000 shares, an increase of 0.3% from the previous total of 10,500,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Aurinia Pharmaceuticals' float size? Aurinia Pharmaceuticals currently has issued a total of 135,100,000 shares. Some of Aurinia Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Aurinia Pharmaceuticals currently has a public float of 119,370,000 shares. How does Aurinia Pharmaceuticals' short interest compare to its competitors? 8.82% of Aurinia Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Aurinia Pharmaceuticals: Krystal Biotech, Inc. (12.15%), Zai Lab Limited Unsponsored ADR (4.19%), Rhythm Pharmaceuticals, Inc. (7.97%), PTC Therapeutics, Inc. (6.77%), Cytokinetics, Incorporated (12.00%), ACADIA Pharmaceuticals Inc. (12.55%), Merus N.V. (7.57%), SpringWorks Therapeutics (9.19%), Avidity Biosciences, Inc. (14.10%), Arcellx, Inc. (15.80%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($69.26 billion), Invesco QQQ ($25.22 billion), iShares Russell 2000 ETF ($20.33 billion), iShares 20+ Year Treasury Bond ETF ($9.99 billion), MicroStrategy Incorporated ($9.12 billion), Canadian Natural Resources Limited ($6.73 billion), SPDR S&P Biotech ETF ($6.52 billion), Invesco S&P 500 Equal Weight ETF ($5.60 billion), Financial Select Sector SPDR Fund ($4.64 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.59 billion). View all of the most shorted stocks. What does it mean to sell short Aurinia Pharmaceuticals stock? Short selling AUPH is an investing strategy that aims to generate trading profit from Aurinia Pharmaceuticals as its price is falling. AUPH shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Aurinia Pharmaceuticals? A short squeeze for Aurinia Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of AUPH, which in turn drives the price of the stock up even further. How often is Aurinia Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AUPH, twice per month. The most recent reporting period available is June, 15 2025. More Short Interest Resources from MarketBeat Related Companies KRYS Short Squeeze ZLAB Short Squeeze RYTM Short Squeeze PTCT Short Squeeze CYTK Short Squeeze ACAD Short Squeeze MRUS Short Squeeze SWTX Short Squeeze RNA Short Squeeze ACLX Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AUPH) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
